About Semax Source: An Independent Research Digest

About Semax Source

Semax Source is an independent editorial project that publishes summaries of the peer-reviewed research literature on Semax, the synthetic ACTH(4-10) heptapeptide studied for neuroprotection, BDNF upregulation, and cognitive effects in rodent and in vitro models. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name 'Source' is editorial framing — it signals that this site is a source of organized research information on the compound, not a vendor or a prescription service. We make no claims about the compound's safety or efficacy for human use. We summarize what the published literature has measured.

The Semax research record is predominantly Russian in origin, concentrated at the Institute of Molecular Genetics of the Russian Academy of Sciences and affiliated institutions. It spans more than thirty years and twenty-one peer-reviewed publications (indexed on this site). We have organized it by theme — mechanism, neuroprotection, BDNF, dosage-in-research, variants — to make it navigable for researchers, clinicians, and scientifically literate general readers who want to understand what the studies actually measured.

We are not affiliated with any Russian research institution, pharmaceutical manufacturer, or peptide supplier. We have no commercial relationship with any company that produces or distributes Semax or its analogs. Every citation on this site links to a verifiable primary source — PubMed, PMC, Springer, Wiley — with no paywalled claims made without a corresponding accessible record.

To contact us with corrections, broken citation reports, or questions about the editorial methodology, use the contact page.

Editorial scope and coverage

The site covers Semax (parent compound, PMID-anchored literature), N-Acetyl Semax, and N-Acetyl Semax Amidate (analog stability and structural variants). It does not cover Selank independently — Semax vs Selank comparison content is limited to direct-comparison studies where both compounds were tested in the same experimental system.

The literature indexed here is peer-reviewed. Forum discussions, anecdotal reports, and vendor marketing are not cited. The 21 citations on this site represent the substantive mechanistic and clinical evidence base identified through PubMed and PMC search as of May 2026. Recent studies from 2024 and 2025 are indexed separately in the research pages to distinguish the historical record from emerging findings.

Where the evidence is thin, fractured, or limited to one national research tradition, we say so. The Ceramica Wabi-Sabi aesthetic of this site is deliberately chosen for this reason: the kintsugi motif maps onto a research record where the seams — the gaps, the unreplicated findings, the Russian-to-Western translation boundary — are part of the documented landscape, not editorial failures to be hidden.

Editorial disclaimer

Semax Source is an editorial publication. It is not a medical practice, a clinical trial sponsor, or a pharmaceutical company. None of the content on this site constitutes medical advice, clinical guidance, or a recommendation for any human use of any compound.

Semax is not approved by the FDA or EMA for any human indication. It is registered as a pharmaceutical in the Russian Federation for cerebrovascular and cognitive indications. Its regulatory status in other jurisdictions varies.

If you are considering any use of Semax or its analogs, consult a licensed clinician in your jurisdiction. This site provides summaries of the published research record — the same record a clinician would consult — but it does not substitute for a clinical evaluation.

For frequently asked questions about Semax including regulatory status and safety data in the preclinical literature, see the FAQ.